In a meta-analysis of 22 clinical trials mostly in patients with hypertension, Elliott and Meyer documented the odds ratio of new-onset T2DM compared with placebo to be highest with diuretics and β-blockers (included studies using predominantly atenolol or metoprolol) and lowest with ARBs and ACE-inhibitors [108]. The gene discussed is ACE; the disease is type 2 diabetes mellitus.